HIV Vaccine. Sunee Sirivichayakul, Ph.D. Faculty of Medicine Chulalongkorn University. August 22, 2014
|
|
- Dominic Hood
- 6 years ago
- Views:
Transcription
1 HIV Vaccine Sunee Sirivichayakul, Ph.D. Faculty of Medicine Chulalongkorn University August 22, 2014
2 Immunity Natural immunity Active natural immunity e.g., infection Passive natural immunity e.g., trans-placental transfer of maternal antibody Acquired immunity Active acquired immunity e.g., vaccination Passive acquired immunity e.g., administration of antibody or immune T cells
3 Immunity: Active vs. passive acquired immunity Differences Active immunization Passive immunization Administration Vaccines, toxoids Antitoxin, -globulin Production of immunity Slowly Immediately Duration of immunity Long (from several months to years) Short (2 weeks to months) Usage Immunoprophylaxis Emergency prophylaxis and therapy
4 Downloaded from: StudentConsult (on 22 January :12 AM) 2005 Elsevier
5 Why do we need a vaccine? To teach the body s natural immune response to learn how to combat many disease-causing microorganisms, especially those lifethreatening microorganisms (to induce memory cells) When one encounters the same microorganisms later, the immune system will respond quicker and more efficient to get rid of them It is much cheaper to prevent than to treat a disease (In a 2005 study on the economic impact of routine childhood immunization in the US, researchers estimated that for every dollar spent, the vaccination program saved more than $5 in direct costs and approximately $11 in additional costs to society). If too many people in a community do not get vaccinations, diseases can reappear. In 1989, there was a measles outbreak in the US which resulted in > 55,000 cases of measles and 136 measlesassociated deaths.
6 Successful vaccine The success of vaccination in eradicating infectious disease is dependent on several properties of the microbes. Vaccines are effective if - the infectious agent does not establish latency - if it does not undergo much or any antigenic variation - if it does not interfere with the host immune response Vaccines are most effective against infections that are limited to human hosts and do not have animal reservoirs. Most vaccines in use today work by inducing humoral immunity (prevent infections by neutralizing and clearing microbes before they gain their foothold in the host) The best vaccines are those that stimulate the development of longlived plasma cells that produce high-affinity antibodies as well as memory B cells.
7 Effectiveness of Vaccines for Some Common Infectious Diseases Disease Maximum Number of Cases (year) Number of Cases in 2009 Percentage Change Diphtheria 206,939 (1921) Measles 894,134 (1941) Mumps 152,209 (1968) Pertussis 265,269 (1934) 13, Polio (paralytic) 21,269 (1952) Rubella 57,686 (1969) Tetanus 1,560 (1923) Haemophilus influenzae type B 20,000 (1984) Hepatitis B 26,611 (1985) 3,
8 Types of vaccines The type of vaccine is typically based on fundamental information about the microbe, such as how it infects cells and how the immune system responds to it, and the regions of the world where the vaccine would be used. Live, attenuated vaccines (closest to natural infection :- BCG, mumps, measles, rubella) Inactivated vaccines (Pertussis, typhoid) Subunit vaccines (recombinant subunit hepatitis B vaccine) Toxoid vaccines (Diphtheria and tetanus toxoid) Conjugate vaccines (Haemophilus influenzae type B (Hib) vaccine) DNA vaccines Recombinant vector vaccines
9 Why an HIV vaccine is needed? Global epidemic No cure once infected Treatment is life-long, expensive and not without side-effects Treatment is not universally accessible and affordable in many resource-limited settings Number of newly treated each year is less than number newly infected each year Treatment may fail
10 HIV/AIDS in Thailand MSM 10-30%
11 Three Decades of Antiretroviral Therapy and the Future Evidences and developments One/ two ARVs Improve survival Three ARVs (HAART) Durable undetectable VL Earlier HAART non-aids death Transmission New TB New strategies Long-acting ARV? Cure? 1981 late 1980 Mid Few ARVs More toxicity More class ARVs More potent PIs But high pill burden More new ARVs More tolerable More OD options More FDC options Single tablet regimens Monthly ARV? Cure? Availability and treatment options
12 HIV-1 vaccine concepts tested in humans in Asian countries (1) Vaccine concept Sponsor HIV-1 subtype or CRF V3 peptides UBI multiclade I (1994) Gp120 in MF59 Chiron B I (1995) Phase (year of initiation) AIDSVAX gp120 B/E in alum AIDSVAX gp120 B/E in alum ALVAC-HIV vcp gp140 or gp120 in polyphosphazene or alum or MF59 Genetech B/CRF01_AE I/II (1995/97) VaxGen B/CRF01_AE III (1998/2003) USAMRMC B/CRF01_AE I/II (2000) Nitayaphan S, et al. Expert Rev Vaccines 2012.
13 HIV-1 vaccine concepts tested in humans in Asian countries (2) Vaccine concept Sponsor HIV-1 subtype or CRF ALVAC-HIV vcp gp120 in alum (RV144) Phase (year of initiation) USAMRMC B/CRF01_AE III (2003) (mostly heterosexual) Adenovirus type 5 Merck B I/II (2003) DNA + fowlpox NCHECR CRF01_AE I (2004) MVA USAMRMC CRF01_AE II (2012) Nitayaphan S, et al. Expert Rev Vaccines 2012.
14 HIV-1 vaccine concepts planned to be tested in Thailand Vaccine concept Sponsor HIV-1 subtype or CRF ALVAC-HIV vcp gp120 in alum late boosts of RV144 vaccinees USAMRMC B/CRF01_AE II (2012) AIDSVAX gp120 B/E in alum USAMRMC B/CRF01_AE II (2012) Phase (year of initiation) ALVAC-HIV vcp AIDSVAX gp120 B/E in alum DNA biojector vs. electroporation + MVA USAMRMC B/CRF01_AE II (2012) USAMRMC Env A, C, D, and gag consensus, CRF01_AE II (2012) Adenovirus type 26 + MVA USAMRMC Mosaic I (2013) Nitayaphan S, et al. Expert Rev Vaccines 2012.
15 Phases of HIV vaccine development Pre-clinical trials: - mice, rabbits and rhesus macaques - have to move ultimately in human trials because no animals have the same immune systems as humans Clinical trials phase I: - small number (20-100) of healthy, uninfected participants at low risk - to test safety (usually by comparing with a control placebo) - can provide initial data on the dose and administration schedule that achieve the optimal immune response - usually last months
16 Phases of HIV vaccine development (2) Phase II trials : - involves hundreds of participants with varying degrees of risk to better characterize the safety and the immune response - can last 2 or more years Phase III trials : - involves several thousand high-risk volunteers to further assess if the vaccine works in preventing infection - can last 3-5 years An experimental vaccine must successfully complete at least three stages of testing in people before it can be licensed.
17 Results of all efficacy trials of HIV vaccine worldwide Vax003 (USA) gp120 (B/B ) + alum Vax004 (Thailand) gp120 (B/E) + alum STEP (USA + Australia), Phambili (South Africa) Ad5-HIV-1 trivalent vaccine (Gag, Pol, Nef) enhanced rate of infection in uncircumcised Ad5-seropositive male volunteers RV144 (Thailand) Canarypox (ALVAC)-Gag Pol Env E + gp120b/e + alum HVTN505 (USA) DNA-Gag, Pol, Env priming + Ad5-Gag Pol Env (A,B,C) boost
18 RV144 Vaccine efficacy of 31.2 % An analysis of the correlates of risk showed that - IgG-binding Abs to scaffolded V1V2 recombinant protein correlated inversely with infection rate - envelope binding plasma IgA correlated directly with infection rate (may diminish the effects of potentially protective Abs) - Neither low levels of V1V2 Abs nor high levels of envspecific IgA Abs were associated with higher rates of infection than we found in the placebo group.
19 HIV nomenclature HIV-1 M (Major) Group : A1, A2, B, C, D, F1, F2, G, H, J, K, and at least 55 CRFs (circulating recombinant forms) i.e., CRF_A/E, CRF_A/G, CRF_A/B HIV-1 N (not-m, not-o) Group (identified in a few individuals in Cameroon, West Africa) HIV-1 O Group (outlier), most commonly found in West Africa HIV-1 P Group (A human isolate closely related to SIVgor was isolated) HIV-2 (closely related to SIVs isolated from sooty mangabeys : A, B, C, F and G)
20 M Group Subtypes A1, A2, B, C, D, F1, F2, G, H, J and K Subtypes and sub-subtypes (a distinctive lineage that is very closely related to a particular subtype, and is not genetically distinct enough to justify calling a new subtype) The sequences within any one subtype or sub-subtype are more similar to each other than to sequences from other subtypes throughout their genomes. These subtypes represent different lineages of HIV, and have some geographical associations.
21 There is nothing for Asian epidemic (CRF01_AE and Asian subtype B!!!
22
23
24 Why mosaic? Extreme diversity of HIV-1 Coverage of viral diversity using mosaics was greatly increased as compared to natural-sequence vaccine candidates, for both variable and conserved proteins (Fisher W, et al; Nat Med 2007; 13 : ) Possibility of matching with 9-amino acid potential epitopes in global gag sequences Mosaic protein Natural protein 9-amino acid matched 74 % 37 % 8/9-amino acid matched 87% 67 %
25 Mosaics can provide excellent coverage of both CRF01 and Asian B GAG with a three protein cocktail Bette Korber, Thomas Leitner. et al LANL, USA
26 Origin of replication Initiate transcription Improve RNA stability Antibiotics resistance gene Directing expression in mammalian cells Basic structure of vector for DNA vaccine
27 Immunization routes Intramuscular (IM) Intradermal (ID) Needle-free (NF) Electroporation
28 Needle Free Injector: New Device to improve immunogenicity Electroporation
29
30
31 BALB/c mouse
32 Anti-p24 WB Results: ID vs NFI ID 100 mg pdna Day 3 Day 7 after last boost Needle Free 50 µg pdna
33
34 Sources of HIV-1 subtypes for the gag, pol, nef mosaic DNA Immunogen Designs of the Chula DNA vaccine In collaboration with Bette Korber (Los Alamos, USA) Gag (3 mosaic cocktail) o CRF01AE: 156 sequences (114 Thai) o B: 72 Asian sequences (8 Thai) Pol (3 mosaic cocktail) o CRF01AE: 101 sequences (76 Thai) o B: 30 Asian sequences (8 Thai) Nef (4 mosaic cocktail) o CRF01AE: 150 sequences (121 Thai) o B: 210 Asian sequences (14 Thai) (sample collection starting 2005)
35 Mosaic envelope Envelope CRF01_AE (68 sequences from , 9 sequences from , 20 sequences from 2011) - 59 HIV subtype B - 3 mosaic : mosaic 1 = CRF01_AE : mosaic 2 = CRF01_AE + B : mosaic 3 = with some modification of mosaic 2 (by filling in some of the gaps)
36 Overall immunogenicity study Pilot immunogenicity study: DNA vaccine alone DNA priming / recombinant vaccinia boosting Mouse immunogenicity study Non-human primate (monkey) immunogenicity study
37 IFN- ELISpot results of HIV-1 gag, pol, nef AE/B Mosaic DNA vaccines (without boosting) in mice P<0.001 P< Methods: Immunization with a combination of 3 gag mosaic, 3 pol mosaic and 4 nef mosaic with a total amount of DNA 100 g (10 g each) on Week 0, 2, 4; mice sacrificed on Week 5 Interpretations: Unlike the gag mosaic, the pol and nef mosaic cocktail results showed an imbalance of specific T cell response as seen by a significant bias toward subtype B specific responses. Thus, approaches to improve AE-specific responses is needed.
38 Immunization Experiments Objective: To study immunogenicity of Asian mosaic HIV-1 AE/B env DNA vaccine in mice by IM electroporation DNA = 100 µg/dose Recombinant vaccinia = 5 x 10 6 pfu/dose (positive control and boosting) Immunization Ags : DNA alone (Week 0, 2, 4) : DNA prime/vaccinia boost (Week 6) Mice sacrificed : 1 week after last immunization
39 Immunogenicity study Cell-mediated immunity: ELISpot using truncated peptides from subtype B and AE Humoral immunity: Anti-gp120/160 titer by western blot Neutralizing antibody
40 Conclusion : Mosaic primed and boosted with env recombinant vaccinia AE induced the highest response when stimulated with AE pooled peptides as compared to boosted with env recombinant vaccinia B or stimulated with B pooled peptides.
41 IFN- ELISpot results of HIV-1 Env AE/B DNA Mosaic (3 cocktail) with/without recombinant vaccine boosting in mice * p<0.005 (vs all other groups) Conclusions: 1. AE/B DNA mosaic alone induced good env-specific IFN producing T cell responses 2. Boosted with HIV-1 AE rvaccinia, but not B rvac, significantly enhanced the responses
42 Pigtailed macaque (Macaca nemestrina)
43 Monkey (pigtailed macaques) experiment N = 12 DNA: gag and env (total of 2 mg per immunization) Intramuscular or Intradermal, both followed by electroporation on Months 0, 1, 2 Agent Dose (mg) Route of administration Frequency and duration pcmvkan 2 mg/dose 1 ID and 1 IM 3x (mo 0, 1 and 2) HIV-1 gag/env DNA vaccine HIV-1 gag/env DNA vaccine 2 mg/dose EP IM 3x (mo 0, 1 and 2) [2 injecton sites/vaccination] 2 mg/dose EP ID 3x (mo 0, 1 and 2) [3 injecton sites/vaccination] Blood collection : Month 0, and 2 weeks after the last immunization for CMI and HMI (binding and neutralizing Abs)
44 ID immunization could induce better responses to both HIV-1 AE or HIV-1 B gag peptide stimulation.
45 There is no different responses to either HIV-1 AE or HIV-1 B peptide stimulations in both IM and ID immunizations.
46 Monkey # Route Tattoo ELISpot (SFU/million PBMC) week 10 Neutralizing Ab Env E Gag E Env B Gag B TH023 1 IM (C) B <20 2 ID (C) B <20 3 IM B IM B (21 against MN) 5 IM B (22 against MN) 6 IM B111103A (30 against MN) 7 IM B <20 8 ID B ID B ID B <20 11 ID B ID B All unstimulated wells (neg) had 0 and anti-cd3-stimulated (pos cont.) wells had >1200 SFU/million PBMC Neutralizing Ab was kindly performed by Dr.Chitraporn Kannasutra and team at AFRIMS.
HIV Vaccine. 15 September 2016 นพ.นคร เปรมศร ผ อ านวยการส าน กงาน โครงการศ กษาว คซ นเอดส ทดลอง
HIV Vaccine 15 September 2016 นพ.นคร เปรมศร ผ อ านวยการส าน กงาน โครงการศ กษาว คซ นเอดส ทดลอง GLOBAL STATISTICS 2015 17 million people were accessing antiretroviral therapy 36.7 million people globally
More information4/14/2016. HIV Vaccines and Immunoprotection: Where Are We? Learning Objectives. After attending this presentation, participants will be able to:
HIV Vaccines and Immunoprotection: Where Are We? Mark J. Mulligan, MD, FIDSA Distinguished Professor of Medicine Emory University School of Medicine Atlanta, Georgia FINAL: 04/01/16 Atlanta, Georgia: Friday,
More informationMay HIV Vaccines: The Basics
May 2018 HIV Vaccines: The Basics Presentation Overview What is a vaccine? How would an HIV vaccine work? Where are we in the search? What is needed now? What is a Vaccine? A substance that teaches the
More informationGOVX-B11: A Clade B HIV Vaccine for the Developed World
GeoVax Labs, Inc. 19 Lake Park Drive Suite 3 Atlanta, GA 3 (678) 384-72 GOVX-B11: A Clade B HIV Vaccine for the Developed World Executive summary: GOVX-B11 is a Clade B HIV vaccine targeted for use in
More informationHIV and Challenges of Vaccine Development
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health HIV and Challenges of Vaccine Development Richard A. Koup, MD INTEREST
More information9/10/2018. Principles of Vaccination. Immunity. Antigen. September 2018
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Principles of Vaccination September 2018 Chapter 1 September 2018 Photographs and images included in
More informationCurrent State of HIV Vaccine Development
Current State of HIV Vaccine Development Sandhya Vasan, MD US Military HIV Research Program Henry M. Jackson Foundation Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand AVAC HVAD
More informationThe History of HIV Vaccine Development
The History of HIV Vaccine Development a short story on 30 years of research å Dr. Jill Gilmour International AIDS Vaccine Initiative Barcelona, 6 October 2013 IAVI is a product-development partnership
More informationVACCINATION. DR.FATIMA ALKHALEDY M.B.Ch.B;F.I.C.M.S/C.M.
VACCINATION DR.FATIMA ALKHALEDY M.B.Ch.B;F.I.C.M.S/C.M. IMMUNIZATION Immunization is defined as the procedure by which the body is prepared to fight against a specific disease. It is used to induce the
More informationGene Vaccine Dr. Sina Soleimani
Gene Vaccine Dr. Sina Soleimani Human Viral Vaccines Quality Control Laboratory (HVVQC) Titles 1. A short Introduction of Vaccine History 2. First Lineage of Vaccines 3. Second Lineage of Vaccines 3. New
More informationAn AIDS vaccine: Why is it so difficult?
An AIDS vaccine: Why is it so difficult? Jaap Goudsmit, MD, PhD Professor of Poverty-related Communicable Diseases, AMC Chairman of the Board CPCD CSO, Crucell Holland BV An AIDS vaccine: Why is it so
More informationVaccines. Vaccines ( continued 1) February 21, 2017 Department of Public Health Sciences
Infectious Disease Epidemiology BMTRY 713 (A. Selassie, DrPH) Lecture 11 Vaccines Past, Present, Future Learning Objectives 1. Identify the various types of vaccines 2. Describe the role of vaccine in
More informationPrinciples of Vaccination
Immunology and Vaccine-Preventable Diseases Immunology is a complicated subject, and a detailed discussion of it is beyond the scope of this text. However, an understanding of the basic function of the
More informationNew Preventive Technology: Providing New Options to Stop the Spread of HIV/AIDS. Dublin, Ireland. June 24, AIDS Vaccines.
New Preventive Technology: Providing New Options to Stop the Spread of HIV/AIDS Dublin, Ireland June 24, 2004 AIDS Vaccines - An R&D Briefing This paper has been prepared by the International AIDS Vaccine
More informationALVAC -HIV and AIDSVAX B/E Prime-Boost HIV-1 Preventive Vaccine Regimen. Results of the Thai HIV Vaccine Trial, RV144
ALVAC -HIV and AIDSVAX B/E Prime-Boost HIV-1 Preventive Vaccine Regimen Results of the Thai HIV Vaccine Trial, RV144 SupachaiRerks-Ngarm, PunneePittisutthithum, SorachaiNitayaphan, JaranitKaewkungwal,
More informationA Quarterly Update on HIV Prevention Research. Vol. 8 No. 2
What is it? What could it do? Key Facts Antibodies Passive immunization is the transfer of pre-made antibodies to a person. Passive immunization using today's pre-made antibodies can involve infusion delivered
More informationCopyright regulations Warning
COMMONWEALTH OF AUSTRALIA Copyright regulations 1969 Warning This material has been reproduced and communicated to you by or on behalf of the University of Melbourne pursuant to part VB of the Copyright
More informationHVTN P5 Vaccine Trials
HVTN P5 Vaccine Trials Erica Andersen-Nissen, PhD Director, Cape Town HVTN Immunology Laboratory Considerations for a Pan-African HIV Vaccine Development Agenda Kigali, Rwanda 16-17 March 2015 HVTN Mission
More informationProfessor Jonathan Weber
THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Professor Jonathan Weber Imperial College, London 1-4 April 2014, Arena and Convention Centre Liverpool THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Professor
More informationPreventive and therapeutic HIV vaccines. Markus Bickel Infektiologikum Frankfurt
Preventive and therapeutic HIV vaccines Markus Bickel Infektiologikum Frankfurt No conflicts to declare Disclosures Background FAQ: by patients and colleagues Publication about promising results, especially
More informationAdvancing HIV Vaccines into Efficacy studies. Glenda Gray WHO PD VAC 7-9 September 2015 Geneva, Switzerland
Advancing HIV Vaccines into Efficacy studies Glenda Gray WHO PD VAC 7-9 September 2015 Geneva, Switzerland What we need to end AIDS: controlling viremia New classes of Drugs Point of care viral load &
More informationVaccination-Strategies
Vaccination-Strategies Active immunity produced by vaccine Immunity and immunologic memory similar to natural infection but without risk of disease. General Rule: The more similar a vaccine is to the disease-causing
More informationFostering Clinical Development for HIV-1 Vaccine
W Fostering Clinical Development for HIV-1 Vaccine Ravimiarenduse alane seminar 9. oktoobril Tallinnas Mart Ustav, PhD CSO, SVP 1 FIT Biotech Founded in 1995 Operations in Tampere, Finland and Tartu, Estonia
More informationProgress in HIV Vaccine Development Magdalena Sobieszczyk, MD, MPH. Division of Infectious Diseases Columbia University Medical Center
Progress in HIV Vaccine Development Magdalena Sobieszczyk, MD, MPH Division of Infectious Diseases Columbia University Medical Center 1 Outline A short history of HIV vaccine design and development Describe
More informationThe Third D: Long Term Solutions to End the Epidemic. Mitchell Warren Executive Director, AVAC 12 February 2014
The Third D: Long Term Solutions to End the Epidemic Mitchell Warren Executive Director, AVAC 12 February 2014 Key clinical trial milestones: HIV vaccine research First HIV vaccine trial opens Phase
More informationHIV 1 Preventive Vaccine Regimen. Community based Trial in Thailand V 144. for the MOPH TAVEG Collaboration
V ALVAC HIV and AIDSVAX B/E Prime Boost HIV 1 Preventive Vaccine Regimen Final Results of the Phase III Community based Trial in Thailand Supachai Rerks Ngarm, Punnee Pittisutthithum, Sorachai Nitayaphan,
More informationHIV Vaccine Clinical Trials at CIDRZ
HIV Vaccine Clinical Trials at CIDRZ Developing a Safe and Effective Vaccine for Prevention of HIV Infections Globally Christine Namakobo Senior Research Nurse Matero Clinical Research Site State of Global
More informationBiomedical Engineering for Global Health. Lecture 10 HIV/AIDS vaccine development
Biomedical Engineering for Global Health Lecture 10 HIV/AIDS vaccine development Review of lecture 9 How do vaccines work? Types ofvaccines: Review of lecture 9 Are vaccines effective? -Edward Jenner s
More informationComments made today contain forward looking statements as described under the Private Securities Litigation Reform Act of Our forward looking
EBOLA HIV January 2015 Comments made today contain forward looking statements as described under the Private Securities Litigation Reform Act of 1995. Our forward looking statements represent our current
More informationPlease read Chapters 5, 6 and 7 of your vaccine text for next Wednesday s lecture. Chapters 9, 17 and 8 for next Friday s lectures
Valerie Daggett Please read Chapters 5, 6 and 7 of your vaccine text for next Wednesday s lecture Chapters 9, 17 and 8 for next Friday s lectures ppt files for first 2 lectures Past exams Principles of
More informationImmunogenicity of ALVAC HIV (vcp1521) and AIDSVAX B/E Prime Boost Vaccination in RV144, Thai Phase III HIV Vaccine Trial
Immunogenicity of ALVAC HIV (vcp1521) and AIDSVAX B/E Prime Boost Vaccination in RV144, Thai Phase III HIV Vaccine Trial M. de Souza, R. Trichavaroj, A. Schuetz, W. Chuenarom, Y. Phuang ngern, S. Jongrakthaitae,
More informationSession 27: Vaccines. Patricia Fitzgerald-Bocarsly May 18, 2009
Session 27: Vaccines Patricia Fitzgerald-Bocarsly May 18, 2009 A brief history of vaccination Immunity: comes from the Latin immunis meaning exempt Concept dates to 430 B.C. when Thucydides, the historian
More informationTrends in vaccinology
Trends in vaccinology Mathieu Peeters, MD Joint Conference of European Human Pharmacological Societies and Joint Conference of European Human Pharmacological Societies and 20th Anniversary of AGAH March
More informationStart Date* Sites Description
076 17 083 180 084 100 085 90 098 94 Inovio rad35 clade A clade A rad clade B clade B PENNVAX-GP IL-12 adjuvant September-11 Seattle The study looks at the immune response of genital and rectal tissues
More informationHIV-1 Subtypes: An Overview. Anna Maria Geretti Royal Free Hospital
HIV-1 Subtypes: An Overview Anna Maria Geretti Royal Free Hospital Group M Subtypes A (1, 2, 3) B C D F (1, 2) G H J K Mechanisms of HIV-1 genetic diversification Point mutations RT error rate: ~1 per
More informationPREVENTION OF INFECTIOUS DISEASES
PREVENTION OF INFECTIOUS DISEASES Loughlin AM & Strathdee SA. Vaccines: past, present and future. In Infectious Disease Epidemiology, 2 nd ed, Jones & Bartlett, 2007; p 374. Loughlin AM & Strathdee SA.
More informationPlanned Vaccine Trials to Follow-up on RV 144. Merlin Robb, MD Deputy Director for Clinical Research MHRP
Planned Vaccine Trials to Follow-up on RV 144 Merlin Robb, MD Deputy Director for Clinical Research MHRP Planned studies are mutually reinforcing and will amplify public health impact and regional relevance
More informationHIV-1 Vaccine Trials: Evolving Concepts and Designs
Send Orders of Reprints at bspsaif@emirates.net.ae 274 The Open AIDS Journal, 2012, 6, 274-288 HIV-1 Vaccine Trials: Evolving Concepts and Designs Open Access Missa P. Sanou 1, Anne S. De Groot 2, Michael
More informationAre we targeting the right HIV determinants?
QuickTime et un décompresseur TIFF (non compressé) sont requis pour visionner cette image. AIDS Vaccine 2009 October 22 nd 2009 - Paris Are we targeting the right HIV determinants? Françoise BARRÉ-SINOUSSI
More informationDevelopment of a Universal T Cell Vaccine. Tomáš Hanke Weatherall Institute of Molecular Medicine University of Oxford United Kingdom
Development of a Universal T Cell Vaccine Tomáš Hanke Weatherall Institute of Molecular Medicine University of Oxford United Kingdom Development of HIV-1 vaccines Induction of cell-mediated responses Immunogens
More informationEDCTP Third Forum PARTNERSHIP AND AFRICAN LEADERSHIP IN VACCINE RESEARCH AND HIV/AIDS DRUG. MBOUP Souleymane
EDCTP Third Forum PARTNERSHIP AND AFRICAN LEADERSHIP IN VACCINE RESEARCH AND HIV/AIDS DRUG MBOUP Souleymane HIV VACCINE IN AFRICA In 2005, 13 new trials of preventive AIDS vaccine candidates began in 9
More informationClinical Trials of Pandemic Vaccines: Key Issues. John Treanor University of Rochester Rochester, NY
Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY Inactivated vaccine approach Proven technology Used successfully in 1957 and 1968 Abundant efficacy data
More informationOngoing HVTN Trials (Enrolling, In Follow-up, and in Long Term Follow-up)
Ongoing HVTN Trials (, In, and in ) HVTN 085 90 HVTN VRC rad5 multiclade 02/2012 Boston - Brigham; Chicago; Nashville; New York - NYBC; New York - NYBC - Bronx; Philadelphia; Rochester; San Francisco;
More informationTrials & Tribulations: on the way to cure: where do HIV Vaccines fit in? Glenda Gray SA HIV Clinicians Society Conference April, 2016
Trials & Tribulations: on the way to cure: where do HIV Vaccines fit in? Glenda Gray SA HIV Clinicians Society Conference 2016 13-16 April, 2016 Scope Rationale for an HIV vaccine RV144 study in Thailand
More informationOngoing HVTN Trials. Protocol N Trial Collaborators HVTN HVTN VRC DAIDS. Study Product(s)
HVTN 076 17 HVTN DNA multiclade rad5 multiclade 09/2011 The study looks at the immune response of genital and rectal tissues to injections of a DNA vaccine followed by a recombinant adenovirus serotype
More informationProfessor Andrew McMichael
BHIVA AUTUMN CONFERENCE 2011 Including CHIVA Parallel Sessions Professor Andrew McMichael University of Oxford 17 18 November 2011, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
More informationProgress on new vaccine strategies against chronic viral infections
Progress on new vaccine strategies against chronic viral infections Jay A. Berzofsky,, Masaki Terabe, Igor M. Belyakov J Clin Invest. 2004;114(4):450-462. https://doi.org/10.1172/jci22674. Review Among
More informationEconomic aspects of viral hepatitis in Turkey. Levent AKIN VIRAL HEPATITIS PREVENTION BOARD MEETING ISTANBUL, TURKEY, NOVEMBER 12-13, 2009
Economic aspects of viral hepatitis in Turkey Levent AKIN VIRAL HEPATITIS PREVENTION BOARD MEETING ISTANBUL, TURKEY, NOVEMBER 12-13, 2009 Vaccines currently recommended for children in National Immunization
More informationGuideline for the immunization of HIV infected persons in Sri Lanka
DOI: http://doi.org/10.4038/joshhm.v3i0.64 Guideline for the immunization of HIV infected persons in Sri Lanka Dr. M. K. Darshanie Mallikarachchi, Consultant Venereologist, Provincial General Hospital
More informationPerspective in novel TB vaccine development Mohamed Ridha BARBOUCHE M.D., Ph.D. Department of Immunology Institut Pasteur de Tunis
Perspective in novel TB vaccine development Mohamed Ridha BARBOUCHE M.D., Ph.D. Department of Immunology Institut Pasteur de Tunis Existing TB Vaccine is not effective for global TB epidemic control BCG
More informationMicro 301 HIV/AIDS. Since its discovery 31 years ago 12/3/ Acquired Immunodeficiency Syndrome (AIDS) has killed >32 million people
Micro 301 HIV/AIDS Shiu-Lok Hu hus@uw.edu December 3, 2012 Since its discovery 31 years ago Acquired Immunodeficiency Syndrome (AIDS) has killed >32 million people In 2011 34.0 million [31.4 35.9 million]
More informationCorrelates of Immunity: RV144 - Lessons Learned
Correlates of Immunity: RV144 - Lessons Learned US Military HIV Research Program (MHRP) Nelson L. Michael, MD, PhD AIDS Vaccine 2010, Atlanta GA 01 October 2010 Outline RV 144 Correlates Discovery Towards
More informationImmunization. Immunization procedure called vaccination and the immunizing agent called vaccine (or serum in historical references)
Vaccines BIT 120 Immunization Immunization: a procedure designed to increase concentrations of antibodies and/or effector T-cells which are reactive against infection (or cancer). Immunization procedure
More informationT cell Vaccine Strategies for HIV, the Virus. With a Thousand Faces
JVI Accepts, published online ahead of print on 13 May 2009 J. Virol. doi:10.1128/jvi.00114-09 Copyright 2009, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationImmunity and how vaccines work
Immunity and how vaccines work Dr Mary O Meara National Immunisation Office Objectives of session An understanding of the following principles Overview of immunity Different types of vaccines and vaccine
More informationCombinatorial Vaccines for AIDS and other Infectious Diseases
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services Combinatorial Vaccines for AIDS
More informationDNA Immunization for HIV Vaccine Development
University of Massachusetts Medical School escholarship@umms GSBS Student Publications Graduate School of Biomedical Sciences 2-25-2014 DNA Immunization for HIV Vaccine Development Yuxin Chen University
More informationVaccines and other immunological antimicrobial therapy 1
Vaccines and other immunological antimicrobial therapy 1 Vaccines Vaccine: a biological preparation that provides active acquired immunity to a particular disease. Vaccine typically contains an agent that
More informationStart Date* Sites Description
HVTN 076 17 HVTN HVTN 084 100 HVTN HVTN 085 90 HVTN HVTN 096 96 HVTN IPPOX EuroVacc GSID USMHRP HVTN 098 94 HVTN Inovio clade B AIDSVAX B/E clade C NYVAC clade C PENNVAX-GP IL-12 adjuvant September-11
More informationFaculty/Presenter Disclosure. HIV Update Outline. Undetectable = Untransmissable HTPN 052. Partner Opposites attract 9/28/2018
Faculty/Presenter Disclosure HIV Update 2018 Dr. Joss de Wet Clinical Assistant Professor Family Medicine UBC Faculty: Joss de Wet Relationships with financial sponsors: Speakers Bureau/Honoraria: Gilead,
More informationVaccines. Magdalena Sobieszczyk, MD, MPH Division of Infectious Diseases Columbia University. Outline
Vaccines Magdalena Sobieszczyk, MD, MPH Division of Infectious Diseases Columbia University Outline Public health impact of vaccines Historical perspective Active vs. Passive Immunization Immune system
More informationDCVMN AND VACCINE SECURITY IN ASEAN REGION. ASEAN Countries on Opportunities for Regional Vaccine Security 1-3 October, 2014.
DCVMN AND VACCINE SECURITY IN ASEAN REGION ASEAN Countries on Opportunities for Regional Vaccine Security 1-3 October, 2014. Phuket - Thailand Developing Countries Vaccine Manufacturers Network (DCVMN)
More informationTrial Collaborators Start Date* Sites Stage HVTN BMGF IPPOX EuroVacc GSID. HVTN DAIDS GSK Sanofi Jun 2017
Ongoing s:, In, Health/AESI Contact(s) 096/EV04 106 107 108 110 A phase 1 double blind placebo-controlled clinical trial to evaluate the safety and to compare the priming ability of NYVAC alone versus
More informationImmunity & How Vaccines Work
Immunity & How Vaccines Work Immunisation Study Day 30 th November 2016 Talk given today by Dr. Mary Fitzgerald Learning outcome To be able to describe in outline the immune system and how vaccines work
More informationPractical Applications of Immunology. Chapter 18
Practical Applications of Immunology Chapter 18 I. Vaccines A. Definition A suspension of organisms or fractions of organisms that is used to induce immunity (immunologic memory). The mechanism of memory
More informationHow does the body defend itself?
Prevention of Infection 2 Immunisation 3 rd BDS B. Martin Major World Causes Of Death COUNTRIES Developing Developed Total x10-6 Population 5400 (80%) 1200 (20%) 6600 CAUSE OF DEATH % % % Infectious diseases
More informationGroup 4: Science and Vaccine Development Recommendations to the MOPH on the RV 144 HIV Phase III Vaccine Trial
rprise HO-Enter WH Group 4: Science and Vaccine Development Recommendations to the MOPH on the RV 144 HIV Phase III Vaccine Trial Dr. Wai Lin Htun Mahidol University 0 Recommendation 1: Durability of Vaccine
More informationHistory and aims of immunisation. Dr Anna Clarke Department of Public Health Dr. Steevens Hospital Dublin 8
History and aims of immunisation Dr Anna Clarke Department of Public Health Dr. Steevens Hospital Dublin 8 Objectives To examine the history of immunisation To explain the aim of immunisation To develop
More informationHerd Protective Effects of Vaccines. John Clemens icddr,b, Dhaka, Bangladesh
Herd Protective Effects of Vaccines John Clemens icddr,b, Dhaka, Bangladesh Promising Vaccine Candidate Phase I. Safe and Immunogenic in Healthy Adults? Yes No Phase II. Safe and Immunogenic in the Target
More information24 26 January 2013, Hong Kong SAR, CHINA. TITLE from VIEW and SLIDE MASTER February 27, 2013
The first WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses 24 26 January 2013, Hong Kong SAR, CHINA 1 TITLE
More informationA Multicistronic DNA Vaccine Induces Significant Protection against Tuberculosis in Mice and Offers Flexibility in the Expressed Antigen Repertoire.
Company LOGO A Multicistronic DNA Vaccine Induces Significant Protection against Tuberculosis in Mice and Offers Flexibility in the Expressed Antigen Repertoire. Fayaz Ahmad Mir, Stefan H. E. Kaufmann,
More informationD-LAB HEALTH SP 725. Jose Gomez-Marquez
SP 725 Jose Gomez-Marquez 1 Vaccine Preventable Diseases Causes of 2.5 million child deaths out of 10.5 million child deaths globally, 2002 Source: WHO Wkly Epidemiol Rec. (2006) 81:189-196. 2 Rationale
More informationA VACCINE FOR HIV BIOE 301 LECTURE 10 MITALI BANERJEE HAART
BIOE 301 LECTURE 10 MITALI BANERJEE A VACCINE FOR HIV HIV HAART Visit wikipedia.org and learn the mechanism of action of the five classes of antiretroviral drugs. (1) Reverse transcriptase inhibitors (RTIs)
More informationVaccination and Immunity
Vaccination and Immunity Eric A. Utt, PhD Director, Worldwide Science Policy Pfizer Inc California Immunization Coalition Summit 2012 Completing the Circle: Ensuring Adult & Adolescent Vaccination for
More informationA global approach to HIV-1 vaccine development
A global approach to HIV-1 vaccine development The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation Published Version Accessed
More informationDEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED
DEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED Viv Peut Kent Laboratory, University of Melbourne, Australia WHY ENVELOPE? Env subject to both humoral and cellular immune responses Perhaps
More informationThe Kitchen Sink. Glenda Gray AIDS vaccine at the cross roads: how to adapt to a new preven9on age? Monday 7 th October, 2013, Barcelona
The Kitchen Sink Glenda Gray AIDS vaccine at the cross roads: how to adapt to a new preven9on age? Monday 7 th October, 2013, Barcelona The only important slide of my presentation. All efficacy trial in
More informationBiotechnology-Based Vaccines. Dr. Aws Alshamsan Department of Pharmaceutics Office: AA87 Tel:
Biotechnology-Based Vaccines Dr. Aws Alshamsan Department of Pharmaceutics Office: AA87 Tel: 4677363 aalshamsan@ksu.edu.sa Objectives of this lecture By the end of this lecture you will be able to: 1.
More informationExpanded Programme on Immunization (EPI):
Expanded Programme on Immunization (EPI): Introduction Four to five million annual deaths could be prevented by 2015 through sustained and appropriate immunization efforts, backed by financial support.
More information1 Principles of Vaccination Immunology and Vaccine-Preventable Diseases... 1 Classification of Vaccines... 4 Selected References...
1 Principles of Vaccination Immunology and Vaccine-Preventable Diseases... 1 Classification of Vaccines... 4 Selected References... 7 2 General Recommendations on Immunization Timing and Spacing of Vaccines...
More informationCommunicable Disease & Immunization
Communicable Disease & Immunization Ingham County Health Surveillance Book 2016 Communicable Disease & Immunization - 1 Communicable Disease & Immunization T he control of communicable disease and immunization,
More informationProtocol Synopsis. Administrative information
Protocol Synopsis Item (SPIRIT item no.) Administrative information Title (1) Introduction Description of research question (6a) Description An optimal schedule for the post-polio eradication era: multicentre
More informationSelected vaccine introduction status into routine immunization
Selected introduction status into routine infant immunization worldwide, 2003 This report summarizes the current status of national immunization schedules in 2003, as reported by Member States in the /UNICEF
More informationHigher priming doses enhance HIV-specific humoral but not cellular. responses in a randomized, double-blind phase Ib clinical trial of
Higher priming doses enhance HIV-specific humoral but not cellular responses in a randomized, double-blind phase Ib clinical trial of preventive HIV-1 vaccines Pierre-Alexandre Bart a,b, Yunda Huang c,
More informationInnate and Cellular Immunology Control of Infection by Cell-mediated Immunity
Innate & adaptive Immunity Innate and Cellular Immunology Control of Infection by Cell-mediated Immunity Helen Horton PhD Seattle Biomedical Research Institute Depts of Global Health & Medicine, UW Cellular
More informationUpdate on Mumps, Pertussis, and Hepatitis A Morbidity Los Angeles County
Update on Mumps, Pertussis, and Hepatitis A Morbidity Los Angeles County Emmanuel Mendoza, MPH Immunization Coalition Meeting October 12, 2017 Los Angeles County Department of Public Health, Vaccine Preventable
More informationProgram: Expanding immunization coverage for children
1 of 7 05/04/2012 20:51 Published on GiveWell (http://givewell.org) Home > Program: Expanding immunization coverage for children Program: Expanding immunization coverage for children In a nutshell The
More informationHIV: RV 144 prime boost HIV vaccine efficacy study
HIV: RV 144 prime boost HIV vaccine efficacy study Nelson L. Michael, M.D., Ph.D Colonel, Medical Corps, U.S. Army Director US Military HIV Research Program (MHRP) Walter Reed Army Institute of Research
More informationVaccine Trial Centre. Established in1984 Funded by WHO on Control of Diarrhea Diseases Full operation in1986
Vaccine Trial Centre Established in1984 Funded by WHO on Control of Diarrhea Diseases Full operation in1986 Past 29 Years of Research Experiences Cholera Vaccine Killed whole cell and B sub-unit oral vaccine
More informationPolio vaccines and polio immunization in the pre-eradication era: WHO position paper. Published in WER 4 June, 2010
Polio vaccines and polio immunization in the pre-eradication era: WHO position paper Published in WER 4 June, 2010 Epidemiology & Background Poliomyelitis (polio) is an acute communicable disease of humans
More informationLichenase: a versatile, stable carrier molecule for vaccine and reagent development
Lichenase: a versatile, stable carrier molecule for vaccine and reagent development R. Mark Jones Center for Molecular Biotechnology, Fraunhofer USA New Cells, New Vaccines VII, From Protein to Product
More informationImmunizations are among the most cost effective and widely used public health interventions.
Focused Issue of This Month Recommended by the Korean Pediatric Society, 2008 Hoan Jong Lee, MD Department of Pediatrics, Seoul National University College of Medicine E mail : hoanlee@snu.ac.kr J Korean
More informationReplicating measles-shiv vaccine induces long term preservation of central memory CD4 cells in the gut of macaques challenged with SHIV89.
Replicating measles-shiv vaccine induces long term preservation of central memory CD4 cells in the gut of macaques challenged with SHIV89.6P Frédéric Tangy Viral Genomics and Vaccination Laboratory Measles
More information8/10/2017. HIV UPDATE 2017 David M Stein DO, FACOI
HIV UPDATE 2017 David M Stein DO, FACOI 1 Current US HIV data 1.1 million HIV positive 1 out of 7 positive are unaware of their status Highest risk in Gay and Bisexual men, young African American men 2
More informationM I C R O B I O L O G Y
ninth edition TORTORA FUNKE CASE M I C R O B I O L O G Y a n i n t r o d u c t i o n 18 Practical Applications of Immunology PowerPoint Lecture Slide Presentation prepared by Christine L. Case Vaccine
More informationEconomics of Vaccine Development A Vaccine Manufacturer s Perspective
Economics of Vaccine Development A Vaccine Manufacturer s Perspective Gerald Voss The Value of Vaccines 2 29 diseases are currently preventable by vaccination Global public health Cervical cancer 1 Diphtheria
More informationHIV/AIDS: vaccines and alternate strategies for treatment and prevention
Ann. N.Y. Acad. Sci. ISSN 0077-8923 ANNALS OF THE NEW YORK ACADEMY OF SCIENCES Online Meeting Report HIV/AIDS: vaccines and alternate strategies for treatment and prevention Yegor Voronin 1 and Sanjay
More informationImmunization (I) Dr. Aws Alshamsan Department of Pharmaceu5cs Office: AA87 Tel:
Immunization (I) Dr. Aws Alshamsan Department of Pharmaceu5cs Office: AA87 Tel: 4677363 aalshamsan@ksu.edu.sa Objectives of this lecture By the end of this lecture you will be able to: 1 Realize the significance
More informationimmunisation in New Zealand
This appendix details the history of. Section A1.1 is a brief summary of when each vaccine was introduced to the National Immunisation Schedule (the Schedule). This summary includes vaccines which were
More informationImmunizations (Guideline Intervals Using The Rule of Six for Vaccines Birth to Six Years)
Immunizations (Guideline Intervals Using The Rule of Six for Vaccines Birth to Six Years) Guideline developed by Shelly Baldwin, MD, in collaboration with the ANGELS Team. Last reviewed by Shelly Baldwin,
More information